|Articles|September 9, 2022
- Pharmaceutical Executive-09-01-2022
- Volume 42
- Issue 9
Pharmaceutical Executive, September 2022 Issue (PDF)
Advertisement
Articles in this issue
almost 4 years ago
ESG: Applying Lessons From Consumer Marketalmost 4 years ago
21st Annual Industry Audit: Pharma Performance Checkalmost 4 years ago
DE&I in Pharma Sales & Marketing: ‘While There’s Work, There’s Promise’almost 4 years ago
The Manufacturing Edge on Path to Marketalmost 4 years ago
How Good is a Good Product Launch?almost 4 years ago
More Than a Name: Vyvgartalmost 4 years ago
Fighting Vision Loss: Vabysmoalmost 4 years ago
A Sleeping Giant?: Quviviqalmost 4 years ago
Next-level Efficacy: MounjaroAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia
2
Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement
3
Pharmaceutical Executive Daily: FDA Approves Lipfendra
4
From Dr. Google to Dr. Claude: Why the Most Important Patient Support Innovation Is Still Human Connection
5